Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

Novartis inks deal with Canadian cannabis firm Tilray

December 18, 2018
Research and Development Marijuana, Novartis, Sandoz, Tilray, cannabis

Shares in Canadian cannabis company Tilray jumped by more than 11% today after the British Columbia-based firm announced its entry …

News
novartis_outside_1

Novartis withdraw marketing application for heart drug

December 17, 2018
Sales and Marketing CHMP, EMA, MI, Novartis, pharma

Swiss multinational Novartis has withdrawn a European Medicines Agency (EMA) marketing application for canakinumab for the prevention of serious events …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

December 14, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Akorn, Boehringer, Novartis, Pfizer, Trump, UK, pharmafile, top 10

Business seemed to be the theme this week as Akorn’s acquisition of Fresenius fell through, while Boehringer announced a restructuring …

News
fda2outsideweb

FDA approves first prescription mobile app for opioid use disorder, courtesy of Sandoz and Pear Therapeutics

December 11, 2018
Manufacturing and Production, Sales and Marketing FDA, Novartis, Pear Therapeutics, app, opioid crisis, opioid epidemic, opioids, pharma, reSET-o

A digital therapeutic launched by Pear Therapeutics and Novartis’ generics and biosimilars division Sandoz has become the first FDA-approved app …

News

Novartis unveils strong longer-term Kymriah data at ASH 2018

December 3, 2018
Research and Development, Sales and Marketing ASH 2018, Cancer, Kymriah, Novartis, leukaemia, pharma

Novartis has lifted the curtain on longer-term analysis data for its CAR-T therapy Kymriah (tisagenlecleucel) at the American Society of …

News

Novartis’ Gilenya scores paediatric EU approval for advanced relapsing-remitting MS

November 29, 2018
Sales and Marketing Europe, Novartis, UK, multiple sclerosis, pharma

Novartis has announced that Gilenya (fingolimod) has received marketing authorisation from the European Commission for the treatment of relapsing-remitting forms …

News
novartis_window

Novartis’ gene therapy Luxturna becomes first approved European therapy for vision loss subtype

November 23, 2018
Medical Communications, Sales and Marketing EU, Europe, Luxturna, Novartis, pharma, vision loss

Novartis has revealed that its one-time gene therapy Luxturna (voretigene neparvovec) has been awarded approval by the European Commission to …

News

Novartis’ Promacta cleared by FDA for first-line use in severe aplastic anaemia

November 19, 2018
Sales and Marketing FDA, Novartis, Promacta, Revolade, US, aplastic anaemia, pharma

Novartis has secured expanded approval from the FDA for Promacta (eltrombopag), allowing it to now be used in combination with …

News
novartis_outside_1

Novartis denies potential split with Sandoz

November 15, 2018
Business Services, Manufacturing and Production Business, M&A, MA, Novartis, Sandoz, acquisition, mergers

Swiss newspaper Tages-Anzeiger has reported that Novartis is preparing for a split with long-term partner Sandoz. The two companies merged …

News
novartis_window

Novartis’ Entresto tops enalapril in stabilised heart failure patients

November 13, 2018
Manufacturing and Production, Research and Development Entresto, Novartis, cardiovascular, enalapril, heart failure, pharma

Novartis has declared new findings for Entresto (sacubitril/valsartan) at the American Heart Association’s (AHA) scientific sessions, showing that the drug proved …

News
gehrynovartis

Novartis cuts 20% of research projects

November 1, 2018
Business Services, Research and Development Business, Novartis, gene therapy, infectious diseases, research

Swiss multinational Novartis has cut a fifth of its research projects, as it abandons 90 of its 430 drug development …

News
shutterstock_273326141

Pfizer and Novartis partner up to develop combo therapies for NASH

October 29, 2018
Research and Development, Sales and Marketing Novartis, Pfizer, liver, nash, pharma

Pfizer and Novartis are set to team up in a non-exclusive partnership aimed at the clinical development of one or …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week

October 19, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, AstraZeneca, Bayer, Novartis, Samsung, Trump, biosimilars, brexit

Business, biosimilars and Brexit are the themes of this week’s top 10. While Roche signed a $1 billion deal with …

News
novartis_window

Novartis snaps up cancer drug developer Endocyte for $2.1 billion

October 18, 2018
Research and Development, Sales and Marketing Cancer, Endocyte, Novartis, pharma

Novartis will shell out $2.1 billion to acquire cancer drug developer Endocyte in a move to leverage the company’s technology …

News
Bayer image

Novartis and Bayer seek to oppose High Court ruling over NHS decision to use cheaper drug

October 16, 2018
Manufacturing and Production Bayer, CCG, NHS, Novartis, avastin, wet AMD

Swiss multinational Novartis have joined German pharma firm Bayer in appealing a High Court ruling over 12 NHS clinical commissioning …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025